Cargando…

Prognostic Significance of PD-L1 Expression in Gastric Cancer Patients with Peritoneal Metastasis

Background: Recently, many studies have explored the relationship between the expression of programmed death ligand 1 (PD-L1) and prognosis in gastric cancer, but there is still controversy. Additionally, few studies have specifically investigated the expression of PD-L1 in patients with peritoneal...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xiao-Jiang, Wei, Cheng-Zhi, Lin, Jun, Zhang, Ruo-Peng, Chen, Guo-Ming, Li, Yuan-Fang, Nie, Run-Cong, Chen, Yong-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377298/
https://www.ncbi.nlm.nih.gov/pubmed/37509642
http://dx.doi.org/10.3390/biomedicines11072003
_version_ 1785079483243429888
author Chen, Xiao-Jiang
Wei, Cheng-Zhi
Lin, Jun
Zhang, Ruo-Peng
Chen, Guo-Ming
Li, Yuan-Fang
Nie, Run-Cong
Chen, Yong-Ming
author_facet Chen, Xiao-Jiang
Wei, Cheng-Zhi
Lin, Jun
Zhang, Ruo-Peng
Chen, Guo-Ming
Li, Yuan-Fang
Nie, Run-Cong
Chen, Yong-Ming
author_sort Chen, Xiao-Jiang
collection PubMed
description Background: Recently, many studies have explored the relationship between the expression of programmed death ligand 1 (PD-L1) and prognosis in gastric cancer, but there is still controversy. Additionally, few studies have specifically investigated the expression of PD-L1 in patients with peritoneal metastasis. Methods: Immunohistochemistry was used to analyze the expression of PD-L1 in gastric cancer patients with peritoneal metastasis. The combined positive score (CPS) was calculated to evaluate the expression of PD-L1, and the clinicopathological data were analyzed to explore prognostic significance. Results: In total, 147 gastric cancer patients with peritoneal metastasis were enrolled. The negative PD-L1 expression was defined as a CPS < 1, and high PD-L1 expression was defined as a CPS ≥ 10. PD-L1 expression with CPS ≥ 1 and CPS-negative was detected in 67 (45.58%) and 80 (54.42%) patients, respectively. High PD-L1 expression at PD-L1 CPS ≥ 10 was detected in 21(14.29%) patients. The median overall survival (OS) was 18.53 months in the CPS < 10 group and 27.00 months in the CPS ≥ 10 group; the OS difference between the two groups was significant (p = 0.015). Multivariate analysis demonstrated that a poor Eastern Cooperative Oncology Group performance score (ECOG PS) (p = 0.002) and severe peritoneal metastasis (p = 0.033) were significantly associated with poor survival, while palliative chemotherapy (p = 0.002) and high PD-L1 expression (p = 0.008) were independent and significantly favorable prognostic factors. Conclusions: Our study demonstrated that PD-L1 expression was widely presented in gastric cancer patients with peritoneal metastasis, while a CPS no less than 10 predicted better prognosis.
format Online
Article
Text
id pubmed-10377298
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103772982023-07-29 Prognostic Significance of PD-L1 Expression in Gastric Cancer Patients with Peritoneal Metastasis Chen, Xiao-Jiang Wei, Cheng-Zhi Lin, Jun Zhang, Ruo-Peng Chen, Guo-Ming Li, Yuan-Fang Nie, Run-Cong Chen, Yong-Ming Biomedicines Article Background: Recently, many studies have explored the relationship between the expression of programmed death ligand 1 (PD-L1) and prognosis in gastric cancer, but there is still controversy. Additionally, few studies have specifically investigated the expression of PD-L1 in patients with peritoneal metastasis. Methods: Immunohistochemistry was used to analyze the expression of PD-L1 in gastric cancer patients with peritoneal metastasis. The combined positive score (CPS) was calculated to evaluate the expression of PD-L1, and the clinicopathological data were analyzed to explore prognostic significance. Results: In total, 147 gastric cancer patients with peritoneal metastasis were enrolled. The negative PD-L1 expression was defined as a CPS < 1, and high PD-L1 expression was defined as a CPS ≥ 10. PD-L1 expression with CPS ≥ 1 and CPS-negative was detected in 67 (45.58%) and 80 (54.42%) patients, respectively. High PD-L1 expression at PD-L1 CPS ≥ 10 was detected in 21(14.29%) patients. The median overall survival (OS) was 18.53 months in the CPS < 10 group and 27.00 months in the CPS ≥ 10 group; the OS difference between the two groups was significant (p = 0.015). Multivariate analysis demonstrated that a poor Eastern Cooperative Oncology Group performance score (ECOG PS) (p = 0.002) and severe peritoneal metastasis (p = 0.033) were significantly associated with poor survival, while palliative chemotherapy (p = 0.002) and high PD-L1 expression (p = 0.008) were independent and significantly favorable prognostic factors. Conclusions: Our study demonstrated that PD-L1 expression was widely presented in gastric cancer patients with peritoneal metastasis, while a CPS no less than 10 predicted better prognosis. MDPI 2023-07-15 /pmc/articles/PMC10377298/ /pubmed/37509642 http://dx.doi.org/10.3390/biomedicines11072003 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Chen, Xiao-Jiang
Wei, Cheng-Zhi
Lin, Jun
Zhang, Ruo-Peng
Chen, Guo-Ming
Li, Yuan-Fang
Nie, Run-Cong
Chen, Yong-Ming
Prognostic Significance of PD-L1 Expression in Gastric Cancer Patients with Peritoneal Metastasis
title Prognostic Significance of PD-L1 Expression in Gastric Cancer Patients with Peritoneal Metastasis
title_full Prognostic Significance of PD-L1 Expression in Gastric Cancer Patients with Peritoneal Metastasis
title_fullStr Prognostic Significance of PD-L1 Expression in Gastric Cancer Patients with Peritoneal Metastasis
title_full_unstemmed Prognostic Significance of PD-L1 Expression in Gastric Cancer Patients with Peritoneal Metastasis
title_short Prognostic Significance of PD-L1 Expression in Gastric Cancer Patients with Peritoneal Metastasis
title_sort prognostic significance of pd-l1 expression in gastric cancer patients with peritoneal metastasis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10377298/
https://www.ncbi.nlm.nih.gov/pubmed/37509642
http://dx.doi.org/10.3390/biomedicines11072003
work_keys_str_mv AT chenxiaojiang prognosticsignificanceofpdl1expressioningastriccancerpatientswithperitonealmetastasis
AT weichengzhi prognosticsignificanceofpdl1expressioningastriccancerpatientswithperitonealmetastasis
AT linjun prognosticsignificanceofpdl1expressioningastriccancerpatientswithperitonealmetastasis
AT zhangruopeng prognosticsignificanceofpdl1expressioningastriccancerpatientswithperitonealmetastasis
AT chenguoming prognosticsignificanceofpdl1expressioningastriccancerpatientswithperitonealmetastasis
AT liyuanfang prognosticsignificanceofpdl1expressioningastriccancerpatientswithperitonealmetastasis
AT nieruncong prognosticsignificanceofpdl1expressioningastriccancerpatientswithperitonealmetastasis
AT chenyongming prognosticsignificanceofpdl1expressioningastriccancerpatientswithperitonealmetastasis